Clinical evaluation of amantadine in the treatment of extrapyramidal syndromes caused by neuroleptic drugs
Bukowczyk, A.; Wasik, A.; Horodnicki, J.
Psychiatria Polska 8(2): 143-148
1974
ISSN/ISBN: 0033-2674 PMID: 4830321 Document Number: 70523
Document emailed within 1 workday
Related Documents
Senard, J.M.; Colomes, M.; Rostin, M.; Clanet, M.; Montastruc, J.L. 1990: Extrapyramidal syndromes caused by flunarizine. Apropos of 6 cases Therapie 45(2): 157-159Blümlein, G. 1997: Successful use of amantadine in treatment of malignant neuroleptic syndrome Psychiatrische Praxis 24(5): 257-258
Janssen, P.A.; Niemegeers, C.J.; Schellekens, K.H. 1965: Is it Possible to Predict the Clinical Effects of Neuroleptic Drugs (Major Tranquillizers) from Animal Data?i. "neuroleptic Activity Spectra" for Rats Arzneimittel-Forschung 15: 104-117
Ambrosetto, C.; Martinelli, P. 1971: Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa Minerva Medica 62(82): 4017-4019
Puca, F.M.; Bricolo, A.; Turella, G. 1972: Effects of L-dopa or amantadine treatment on the spindles of sleep in Parkinson's syndromes Revue Neurologique (Paris) 127(2): 313
Urusmambetov, S.N. 1971: The clinical picture and treatment of ganglionic syndromes caused by injury Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 71(5): 650-656
Rojtman, M.; Apter, E.; Lahav, S.; Tiano, S. 1981: Amantadine in malignant neuroleptic syndrome Harefuah 100(7): 333
Eben, E.; Ackenheil, M.; Rüther, E. 1978: Norepinephrine turnover under neuroleptic treatment of schizophrenic syndromes Arzneimittel-Forschung 28(9): 1498
Varese, L.A. 1971: Treatment with immunosuppressive drugs in primary nephrotic syndromes in the pediatric age. Clinical studies Minerva Pediatrica 23(6): 262-266
McCarron, M.M.; Boettger, M.L.; Peck, J.J. 1982: A case of neuroleptic malignant syndrome successfully treated with amantadine Journal of Clinical Psychiatry 43(9): 381-382
2004: Extrapyramidal reactions to SSRI antidepressant + neuroleptic combinations Prescrire International 13(70): 57
Elie, R.; Gagnon, M.A.; Gauthier, R.; Jéquier, J.C. 1975: Effects of neuroleptic withdrawal on the drug-induced extrapyramidal syndrome of chronic schizophrenia L'Union Medicale du Canada 104(6): 909-914
Saran, B.M.; Klein, M.S.; Benay, E.M. 1980: Clinical evaluation of amantadine and haloperidol in Huntington's chorea Journal of Clinical Psychiatry 41(6): 221
Von Domarus, H. 1973: Extrapyramidal motor disorders in neuroleptic therapy (apparent recurring luxation of mandibular joints) Deutsche Zahnarztliche Zeitschrift 28(11): 1085-1088
Sigwald, J.; Raymondeaud, C.; Piot, C. 1973: Method for appraisal and measurement of extrapyramidal symptoms and signs. Clinical evaluation of Parkinsonism. Value in the evaluation of severeness, in the estimation of the evolutive potential, in the appreciation as strict as possible of the effectiveness of antiparkinson therapy La Semaine des Hopitaux: Organe Fonde Par l'Association d'Enseignement Medical des Hopitaux de Paris 49(10): 693-704
Erenberg, G. 1992: Treatment of Tourette syndrome with neuroleptic drugs Advances in Neurology 58: 241-243
Nakazono, Y.; Abe, H.; Murakami, H.; Koyabu, N.; Isaka, Y.; Nemoto, Y.; Murata, S.; Tsutsumi, Y.; Ohtani, H.; Sawada, Y. 2005: Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients International Journal of Clinical Pharmacology and Therapeutics 43(4): 163-171
Schergna, E. 1970: Recent therapeutic conquests in extrapyramidal syndromes Minerva Medica 61(101): 5829-5835
Ciuca, I.; Bulandra, R.; Serbanesco, L.; Ninosu, N. 1972: Comparative value of L-dopa, amantadine, anticholinergics, and their combinations in parkinsonian syndromes Revue Neurologique (Paris) 127(2): 305-308
Badalian, L.O.; Skvortsov, I.A.; Kamennykh, L.N.; Grigorian, A.V. 1977: Electroneuromiographic study of extrapyramidal syndromes from the point of view of age Zhurnal Eksperimental'noi i Klinicheskoi Meditsiny 17(4): 57-63